AVANIR to Present at the Deutsche Bank 34th Annual Health Care Conference

ALISO VIEJO, Calif., May 12, 2009 - AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced that Keith Katkin, President and Chief Executive Officer, will present at the Deutsche Bank 34th Annual Health Care Conference on Tuesday, May 19th at 1:15 p.m. Eastern time (10:15 a.m. Pacific time) in Boston. The Deutsche Bank Health Care Conference is a leading health care industry event attracting over 125 of the industry's most prestigious public and private companies. The conference provides participating companies with the opportunity to present to institutional investors and industry experts. For more information visit www.conferences.db.com.

A live audio webcast of the presentation will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary audio software. An archive of Mr. Katkin's presentation at the Deutsche Bank Health Care Conference will be available on the Company's website for 30 days.

About AVANIR

AVANIR Pharmaceuticals, Inc. is focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, inflammation, and infectious diseases. AVANIR's lead product candidate, Zenvia™, is being developed for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic (DPN) pain. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com and further information about pseudobulbar affect can be found at www.PBAinfo.org.

To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0

AVANIR Investor Contacts
Eric Benevich or Brenna Mullen, 949-389-6700
ir@avanir.com

May 12, 2009